SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 96 filers reported holding SPERO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $11,000 | -98.3% | 14,966 | -79.5% | 0.00% | – |
| Q1 2022 | $636,000 | -47.0% | 73,070 | -2.6% | 0.00% | – |
| Q4 2021 | $1,200,000 | -12.2% | 75,000 | +1.1% | 0.00% | – |
| Q3 2021 | $1,366,000 | +46.9% | 74,207 | +11.4% | 0.00% | – |
| Q2 2021 | $930,000 | -0.1% | 66,595 | +5.4% | 0.00% | – |
| Q1 2021 | $931,000 | -31.3% | 63,172 | -9.6% | 0.00% | – |
| Q4 2020 | $1,355,000 | +135.7% | 69,883 | +35.6% | 0.00% | – |
| Q3 2020 | $575,000 | -14.9% | 51,526 | +3.2% | 0.00% | – |
| Q2 2020 | $676,000 | +82.2% | 49,937 | +8.4% | 0.00% | – |
| Q1 2020 | $371,000 | +2.2% | 46,064 | +21.9% | 0.00% | – |
| Q4 2019 | $363,000 | -8.1% | 37,774 | +1.5% | 0.00% | – |
| Q3 2019 | $395,000 | 0.0% | 37,223 | +8.6% | 0.00% | – |
| Q2 2019 | $395,000 | -8.1% | 34,279 | +2.1% | 0.00% | – |
| Q1 2019 | $430,000 | +90.3% | 33,571 | -8.6% | 0.00% | – |
| Q4 2018 | $226,000 | -22.9% | 36,716 | +31.9% | 0.00% | – |
| Q3 2018 | $293,000 | -19.3% | 27,828 | +12.7% | 0.00% | – |
| Q2 2018 | $363,000 | +79.7% | 24,689 | +73.9% | 0.00% | – |
| Q1 2018 | $202,000 | – | 14,199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
| Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
| VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
| AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
| Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
| BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
| DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
| Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
| Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
| Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |